FDA fast tracks Amgen’s Blincyto leukemia drug
Thousand Oaks-based biotech giant Amgen announced March 29 that the U.S. Food and Drug Administration has fast-tracked the company’s leukemia drug Blincyto for priority review. The drug increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. It almost doubled median overall survival versus chemotherapy among adult patients Read More →
Read More →Law firm probing Sientra board of directors
The law firm of Brodsky & Smith has announced an investigation into the board of directors at Sientra, a breast implant manufacturing firm based in Goleta. According to a news release from the law firm, the investigation comes after previous litigation. The complaint alleges that the defendants made false and misleading statements, including failing to Read More →
Read More →500 Amgen employees to be re-assigned, relocated or laid off
Nearly 500 Amgen employees in Thousand Oaks have been notified that they will be re-assigned, relocated or laid off as part of a restructuring plan. The biotech giant informed employees on March 22 that they will be reassigned to a new Tampa Bay, Fla. facility and research and development offices in Cambridge, Mass. and South Read More →
Read More →Amgen gets European approval for biosimilar of Humira
Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →
Read More →Tri-county hospitals oppose Trump health care bill
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →